Eli Lilly and Co. to expand its NYC research center

Conversation with The Cancer Letter Regulatory News

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.

November 14, 2025

Vol.51 No.42

By Paul Goldberg

Guest Editorial

Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA

Rick Pazdur’s appointment as director of the FDA’s Center for Drug Evaluation and Research (CDER) comes at exactly the right moment, both for the agency and for the patients it serves.

November 14, 2025

Vol.51 No.42

By Ellen V. Sigal

Clinical Regulatory News

FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

Top FDA officials said the agency is in the process of removing the black box safety warnings from all forms of menopausal hormone therapy, including creams, pills, and other treatments prescribed to ease the symptoms of menopause and perimenopause.

November 14, 2025

Vol.51 No.42

By Claire Marie Porter

Clinical Trials & Tribulations

Smoldering multiple myeloma: Rethinking the waiting game

With the recent FDA approval of daratumumab for high-risk smoldering multiple myeloma, the moment is ripe to revisit the evolution of our understanding of smoldering multiple myeloma. This development not only underscores the growing recognition of early intervention but also invites a broader reflection on the biological insights and therapeutic strategies that have shaped—and continue to shape—this transitional disease state.

November 14, 2025

Vol.51 No.42

By C. Ola Landgren

Advancing symptom science at City of Hope and across the globe

The landscape of cancer treatment is rapidly evolving. Increasingly, there is recognition that care must go beyond treating the disease itself—it must also address the whole person and the debilitating symptoms patients experience during and after treatment.

How a neuroendocrine cancer survivor fueled 20 years of research
NETRF celebrates 20 years, $40 million in research funding

This year marks the Neuroendocrine Tumor Research Foundation’s 20th anniversary. Established as the Caring for Carcinoid Foundation by Nancy Lindholm in 2005, NETRF has served as one of the few funding sources for neuroendocrine cancers since its inception.

November 14, 2025

Vol.51 No.42

Eli Lilly and Co. to expand its NYC research center

YOU MAY BE INTERESTED IN

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA

FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

Smoldering multiple myeloma: Rethinking the waiting game

Advancing symptom science at City of Hope and across the globe

How a neuroendocrine cancer survivor fueled 20 years of research
NETRF celebrates 20 years, $40 million in research funding

Renew today!

Subscriber content

Never miss an issue!

Login

Eli Lilly and Co. to expand its NYC research center

YOU MAY BE INTERESTED IN

Richard Pazdur, a respected insider with a plan to reengineer FDA, steps in as CDER director

Rick Pazdur’s CDER appointment comes at exactly the right moment for FDA

FDA to remove black box warnings on hormone therapy for menopauseTrump-era “gold standard science” is not to be confused with gold standard of scientific evidence

Smoldering multiple myeloma: Rethinking the waiting game

Advancing symptom science at City of Hope and across the globe

How a neuroendocrine cancer survivor fueled 20 years of researchNETRF celebrates 20 years, $40 million in research funding

Never miss an issue!

Login

FDA to remove black box warnings on hormone therapy for menopause
Trump-era “gold standard science” is not to be confused with gold standard of scientific evidence

How a neuroendocrine cancer survivor fueled 20 years of research
NETRF celebrates 20 years, $40 million in research funding